Read Gene

Read Gene Liabilities

The The Liabilities of Read Gene (RDG.WA) as of Nov 5, 2026 is 12.14 M PLN. In the previous year, The Liabilities was 11.67 M PLN — a change of 4.05% (higher).

Liabilities

12.14 MPLN

YoY

4.05%

Last updated:

In 2025, Read Gene's total liabilities amounted to 12.14 M PLN, a 4.05% difference from the 11.67 M PLN total liabilities in the previous year.

The Read Gene Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
12.56 M PLN
Jan 1, 2019
11.88 M PLN
Jan 1, 2020
11.68 M PLN
Jan 1, 2021
9.98 M PLN
Jan 1, 2022
10.14 M PLN
Jan 1, 2023
10.97 M PLN
Jan 1, 2024
11.67 M PLN
Jan 1, 2025
12.14 M PLN
The Read Gene Liabilities history
YEARLiabilitiesYoY
12.14 MPLN+4.05%
11.67 MPLN+6.40%
10.97 MPLN+8.19%
10.14 MPLN+1.61%
9.98 MPLN-14.61%
11.68 MPLN-1.68%
11.88 MPLN-5.41%
12.56 MPLN-15.81%
14.92 MPLN-0.40%
14.98 MPLN—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Read Gene Stock analysis

What does Read Gene do? Read Gene SA generates revenue through medical research and testing services, focusing on malignant tumor detection, prevention, and treatment. The company offers breast cancer, colon cancer, and prostate cancer tests, along with medical consultancy, DNA tests, and supplements. Its subsidiary Dieta Antyrakowa Read-Gene Sp. z o.o. supports these services, while major shareholder GEN-PAT-MED Sp. z o.o. provides strategic backing. Clients include patients seeking cancer diagnostics and preventive care, as well as healthcare providers integrating these tests into treatment protocols. The firm's chemoprevention, clinical trials, and genetic testing specialties drive product sales to hospitals, clinics, and individual consumers. Breast cancer, colon cancer, and prostate cancer tests are key revenue streams, complemented by DNA tests and supplements. Medical consultancy services cater to institutions requiring expert guidance on cancer-related health strategies. Read Gene SA's product portfolio is structured around three core fields: chemoprevention, clinical trials, and genetic testing. The company monetizes genetic testing services, particularly for breast, colon, and prostate cancers, alongside DNA tests and supplements. Healthcare institutions and private clients form the primary customer segments, with Dieta Antyrakowa Read-Gene Sp. z o.o. serving as the operational arm for these offerings. Read Gene is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Read Gene's Liabilities

Read Gene's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Read Gene's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Read Gene's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Read Gene's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Read Gene’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Read Gene stock

The Liabilities of Read Gene is 12.14 M PLN in 2025.

The Liabilities of Read Gene changed from 11.67 M PLN to 12.14 M PLN, representing a 4.05% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Read Gene since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's PLN is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Read Gene historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Read Gene

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Read Gene